Next‐generation cancer treatments are expected not only to target cancer cells but also to
simultaneously train immune cells to combat cancer while modulating the immune …

Extracellular vesicles (EVs) are natural lipid nanoparticles secreted by most types of cells. In
malignant cancer, EVs derived from cancer cells contribute to its progression and metastasis …

Tumour-derived exosomes (T-EXOs) impede immune checkpoint blockade therapies,
motivating pharmacological efforts to inhibit them. Inspired by how antiviral curvature …

Extracellular vesicles (EVs) carrying tumor cell-derived programmed death-ligand 1 (PD-L1)
interact with programmed death 1 (PD-1)-producing T cells, thus significantly lowering a …

Tumor-derived extracellular vesicles (TDEs) have potential for therapeutic cancer vaccine
applications since they innately possess tumor-associated antigens, mediate antigen …

With the development of oncology, immunotherapy holds great promise for tumor treatment.
However, immunogenic cell death (ICD), an important stimulator of immune response, often …

PARP inhibitors (PARPi) have changed the treatment paradigm of high-grade serous
ovarian cancer (HG-SOC). However, the impact of this class of inhibitors in HG-SOC patients …

Simple Summary Novel pharmacological approaches are needed to improve treatments of
advanced cancers, despite the considerable benefit of immunotherapy. New drugs are …

The tumor microenvironment (TME) plays a central role in the development of cancer. Within
this complex milieu, the endothelin (ET) system plays a key role by triggering epithelial-to …

Tumor stroma plays an important role in the occurrence, development, and metastasis of
colorectal cancer (CRC). The dense collagenous stroma forms a physical barrier for …